Claims

1. An oral dosage form that enhances the oral bioavailability of zoledronic acid in a mammal, comprising zoledronic acid in the disodium salt form.

2. The oral dosage form of claim 1, wherein the oral dosage form is configured to provide an area under the plasma concentration curve (AUC) of zoledronic acid of 4 ng•h/mL to 2000 ng•h/mL to the mammal each time the dosage form is to be administered.

3. The oral dosage form of claim 1 or claim 2, wherein the mammal is a human being.

4. The oral dosage form of any one of claims 1 to 3, wherein the dosage form is a solid.

5. The oral dosage form of any preceding claim, wherein the oral dosage form contains 10 mg to 300 mg of zoledronic acid.

6. The oral dosage form of claim 5, wherein the oral dosage form contains 10 mg to 50 mg of zoledronic acid.

7. The oral dosage form of claim 5, wherein the oral dosage form contains 50 mg to 150 mg of zoledronic acid.

8. The oral dosage form of claim 5, wherein the oral dosage form contains 150 mg to 300 mg of zoledronic acid.

9. The oral dosage form of any preceding claim, wherein the dosage form is substantially free of bioavailability-enhancing agents.

10. Use of zoledronic acid in the manufacture of a solid oral dosage form for the treatment of complex regional pain syndrome, low back pain or arthritis pain in a mammal in need thereof, wherein the solid oral dosage form is configured to provide an area under the plasma concentration curve (AUC) of zoledronic acid of 1 ng•hr/mL to 700 ng•hr/mL to the mammal each time the dosage form is to be administered.

11. Use of zoledronic acid in the manufacture of an oral dosage form for the treatment of complex regional pain syndrome, low back pain or arthritis pain in a human in need thereof, wherein the oral dosage form is configured to provide an area under the plasma concentration curve (AUC) of zoledronic acid of 1 ng•hr/mL to 700 ng•hr/mL to the human each time the dosage form is to be administered.

12. The use of claim 10, wherein the mammal is a human being.

13. The use of claim 11, wherein the dosage form is a solid.

14. The use of any one of claims 10 to 13, wherein the oral dosage form contains 10 mg to 300 mg of zoledronic acid.

15. The use of claim 14, wherein the oral dosage form contains 10 mg to 50 mg of zoledronic acid.

16. The use of claim 14, wherein the oral dosage form contains 50 mg to 150 mg of zoledronic acid.

17. The use of claim 14, wherein the oral dosage form contains 150 mg to 300 mg of zoledronic acid.

18. The use of any one of claims 10 to 17, wherein the oral dosage form is substantially free of bioavailability-enhancing agents.

19. The use of any one of claims 10 to 18, wherein the mammal or human receives a six week dose of zoledronic acid that is between about 200 mg and about 500 mg.

20. The use of claim 19, wherein the six week dose of zoledronic acid is administered in six weekly doses.

21. The use of claim 20, wherein the weekly doses comprise about 35 mg to about 80 mg of zoledronic acid.

22. Use of zoledronic acid in the disodium salt form in the manufacture of an oral dosage form for the treatment of complex regional pain syndrome, low back pain or arthritis pain, wherein the dosage form enhances the oral bioavailability of zoledronic acid.

23. Use of zoledronic acid in the manufacture of an oral dosage form for the treatment of complex regional pain syndrome, low back pain or arthritis pain, wherein the oral dosage form is configured to provide an area under the plasma concentration curve (AUC) of zoledronic acid of 50 ng•hr/mL to 500 ng•hr/mL each time the dosage form is administered, and wherein the dosage form is intended to be administered to a human being.

24. Use of zoledronic acid in the manufacture of a solid oral dosage form for the treatment of complex regional pain syndrome, low back pain or arthritis pain, wherein the solid oral dosage form is configured to provide an area under the plasma concentration curve (AUC) of zoledronic acid of 50 ng•hr/mL to 500 ng•hr/mL each time the dosage form is to be administered to a mammal.